<SEC-DOCUMENT>0001193125-23-259657.txt : 20231020
<SEC-HEADER>0001193125-23-259657.hdr.sgml : 20231020
<ACCEPTANCE-DATETIME>20231020090525
ACCESSION NUMBER:		0001193125-23-259657
CONFORMED SUBMISSION TYPE:	FWP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20231020
DATE AS OF CHANGE:		20231020

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Abivax S.A.
		CENTRAL INDEX KEY:			0001956827
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-274780
		FILM NUMBER:		231336046

	BUSINESS ADDRESS:	
		STREET 1:		7 BD HAUSSMANN
		CITY:			PARIS
		STATE:			I0
		ZIP:			75009
		BUSINESS PHONE:		01 53 83 09 63

	MAIL ADDRESS:	
		STREET 1:		7 BD HAUSSMANN
		CITY:			PARIS
		STATE:			I0
		ZIP:			75009

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Abivax S.A.
		CENTRAL INDEX KEY:			0001956827
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP

	BUSINESS ADDRESS:	
		STREET 1:		7 BD HAUSSMANN
		CITY:			PARIS
		STATE:			I0
		ZIP:			75009
		BUSINESS PHONE:		01 53 83 09 63

	MAIL ADDRESS:	
		STREET 1:		7 BD HAUSSMANN
		CITY:			PARIS
		STATE:			I0
		ZIP:			75009
</SEC-HEADER>
<DOCUMENT>
<TYPE>FWP
<SEQUENCE>1
<FILENAME>d609070dfwp.htm
<DESCRIPTION>FWP
<TEXT>
<HTML><HEAD>
<TITLE>FWP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to Rule 433 of the Securities Act of 1933 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Issuer Free Writing Prospectus dated October&nbsp;20, 2023 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration Statement <FONT STYLE="white-space:nowrap">No.&nbsp;333-274780</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g609070g43a95.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abivax<B> </B>announces the pricing of its Initial Public Offering on the Nasdaq Global Market </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PARIS, France, October</B><B></B><B>&nbsp;20, 2023 &#150; 3:00 p.m. (CEST)</B> &#150; Abivax SA (Euronext Paris: FR0012333284 &#150; ABVX)
(&#147;<B>Abivax</B>&#148; or the &#147;<B>Company</B>&#148;), a clinical-stage biotechnology company focused on developing therapeutics that harness the body&#146;s natural regulatory mechanisms to modulate the immune response in patients with
chronic inflammatory diseases, announced today the pricing of its initial public offering on the Nasdaq Global Market by way of a capital increase of 20,325,500 new ordinary shares (the &#147;<B>New Shares</B>&#148;), consisting of a public offering
of 18,699,460 ordinary shares in the form of American Depositary Shares (&#147;<B>ADSs</B>&#148;), each representing the right to receive one ordinary share, in the United States (the &#147;<B>U.S. Offering</B>&#148;) and a concurrent offering of
1,626,040 ordinary shares in certain jurisdictions outside of the United States to certain investors (the &#147;<B>European Private Placement</B>&#148; and together with the U.S. Offering, the &#147;<B>Global Offering</B>&#148;). The offering price
was set at $11.60 per ADS in the U.S. Offering and a corresponding offering price of &#128;10.9864 per ordinary share based on an exchange rate of &#128;1.00 = $1.0559 as published by the European Central Bank on October&nbsp;19, 2023. The aggregate
gross proceeds are expected to be approximately $235.8&nbsp;million, equivalent to approximately &#128;223.3&nbsp;million, before deduction of underwriting commissions and estimated expenses payable by the Company. The Global Offering is expected to
close on October&nbsp;24, 2023, subject to the satisfaction of customary closing conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All securities to be sold in the Global Offering will be
offered by the Company. The ADSs have been approved for listing on the Nasdaq Global Market and are expected to begin trading on October&nbsp;20, 2023 under the ticker symbol &#147;ABVX&#148;. The Company&#146;s ordinary shares are listed on the
regulated market of Euronext Paris (&#147;<B>Euronext Paris</B>&#148;) under the symbol &#147;ABVX&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ordinary shares underlying the ADSs sold in
the Global Offering will be subject to an application for admission to trading on Euronext Paris (Compartment B) on the same trading line as the existing shares under the same ISIN code FR0012333284 and are expected to be admitted to trading on
October&nbsp;24, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Morgan Stanley and Leerink Partners are acting as joint global coordinators for the proposed Global Offering and joint bookrunners
for the U.S. Offering. LifeSci Capital is acting as lead manager for the proposed U.S. Offering. Bryan, Garnier&nbsp;&amp; Co is acting as European lead manager for the proposed European Private Placement (collectively, the
&#147;<B>Underwriters</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Namsen Capital is acting as Abivax&#146;s capital markets advisor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pricing of the Global Offering and Discount </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offering price was set at $11.60 per ADS. The offering price per ADS corresponds to the offering price of &#128;10.9864 per ordinary share based on the
October&nbsp;19, 2023 exchange rate of &#128;1.00 = $1.0559. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The public offering price per ordinary share in euros (&#128;10.9864) is equal to the volume
weighted-average price of the Company&#146;s ordinary shares on Euronext Paris over the last three (3)&nbsp;trading days preceding the start of the offering (i.e., 16th, 17th and 18th of October 2023), less a discount of 9.4%, and is determined by
the Company in compliance with the 15th resolution of the Company&#146;s combined general shareholders&#146; meeting held on June&nbsp;5, 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Type
of Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The New Shares will be issued through a capital increase without shareholders&#146; preferential subscription rights by way of a public
offering excluding offerings referred to in Article <FONT STYLE="white-space:nowrap">L.&nbsp;411-2</FONT> 1&deg; of the French Monetary and Financial Code (<I>Code mon&eacute;taire et financier</I>) and under the provisions of Article <FONT
STYLE="white-space:nowrap">L.225-136</FONT> of the French Commercial Code (<I>Code de commerce</I>) and pursuant to the fifteenth and nineteenth resolutions of the Company&#146;s combined general shareholders&#146; meeting held on June&nbsp;5, 2023.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
has granted the Underwriters an option to purchase (the &#147;<B>Option</B>&#148;), for a <FONT STYLE="white-space:nowrap">30-day</FONT> period (until November&nbsp;20, 2023), up to 3,048,825 additional ADSs and/or ordinary shares, which represents
15% of the aggregate amount of New Shares to be issued in the Global Offering, at the same offering price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stabilization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Global Offering, the Underwriters may over-allot the securities or effect transactions with a view to supporting, stabilizing, or
maintaining the market price of the securities at a level higher than which might otherwise prevail in the open market. However, there is no assurance that the stabilizing manager will take any stabilization action and, if begun, may be ended at any
time without prior notice. Any stabilization action or over-allotment shall be carried out in accordance with all applicable rules and regulations and may be undertaken on the Nasdaq Global Market and/or Euronext Paris. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dilution </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the issuance of 20,325,500 New Shares
in the Global Offering (including ordinary shares in the form of ADSs), the number of ordinary shares held by the existing shareholders after the Global Offering would be 67.7% of the total number of ordinary shares (including ordinary shares in the
form of ADSs) outstanding after the Global Offering. If the Underwriters exercise their option to purchase 3,048,825 additional ADSs and/or ordinary shares in full, the number of ordinary shares held by the existing shareholders after the Global
Offering would be 64.5% of the total number of ordinary shares (including ordinary shares in the form of ADSs) outstanding after the Global Offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Estimated Proceeds from the Global Offering&#151;Reasons of the offering&#151;Use of proceeds </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The gross proceeds of the sale of 20,325,500 New Shares, including ordinary shares in the form of ADSs, in the Global Offering is expected to be approximately
$235.8&nbsp;million (&#128;223.3 million), assuming no exercise of the Underwriters&#146; Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company estimates that the net proceeds of the
Global Offering will be approximately $212.2&nbsp;million (&#128;201.1 million), after deducting approximately $16.5&nbsp;million (&#128;15.6 million) in underwriting commissions and approximately $7.0&nbsp;million (&#128;6.6 million) in estimated
offering expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expects to use the net proceeds from the Global Offering as follows (assuming an exchange rate of &#128;1.00 = $1.0559,
the exchange rate on October&nbsp;19, 2023): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately &#128;160.0&nbsp;million ($168.9 million) to fund the development of obefazimod for UC;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately &#128;14.0&nbsp;million ($14.8 million) to fund the development of obefazimod for CD; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remainder for working capital and for other general corporate purposes, including in the continued research
to identify new compounds and the payment of maturities of existing debt agreements as they become due (mostly allocated to payments under the Kreos / Claret Financing (as defined below), and assuming that the Company will repay the Heights
Financing (as defined below) through the issuance of new shares instead of making cash payments). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company believes that the
anticipated net proceeds from the Global Offering, together with its current cash and cash equivalents, will allow it to finance its operations through (i)&nbsp;the announcement of its <FONT STYLE="white-space:nowrap">top-line</FONT> data from its
Phase 3 <FONT STYLE="white-space:nowrap">ABTECT-1</FONT> and <FONT STYLE="white-space:nowrap">ABTECT-2</FONT> induction trials for UC and (ii)&nbsp;the announcement of its <FONT STYLE="white-space:nowrap">top-line</FONT> data from its Phase 2a
induction trial for CD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company believes that based on its current clinical plan and its anticipated net proceeds from the Global Offering, together
with (a)&nbsp;its existing cash and cash equivalents of &#128;114.4&nbsp;million as of June&nbsp;30, 2023, (b) the net proceeds of the August 2023 drawdown of the first tranches of the financing agreements entered into with entities affiliated with
Kreos Capital (&#147;<B>KC</B>&#148;) and Claret European Growth Capital (the &#147;<B>Kreos / Claret Financing</B>&#148;) and entities affiliated with Heights Capital Management (the &#147;<B>Heights Financing</B>&#148;), collectively amounting to
&#128;27.2&nbsp;million (net of repayments of all outstanding amounts that remained due under the prior two financing agreements entered into with KC and the OCEANE bonds), (c) the anticipated net proceeds from the drawdown of the second tranche of
the Kreos / Claret Financing, amounting to &#128;25&nbsp;million (which is a portion of the total available drawdown of &#128;65&nbsp;million from the Kreos / Claret Financing and the Heights Financing) and (d)&nbsp;the expected Research Tax Credit
(CIR) reimbursements would enable the Company to fund its operations through the fourth quarter of 2025. Under these assumptions and based on its current clinical plan, the Company would have sufficient funds to finance its operations through
(i)&nbsp;the announcement of its <FONT STYLE="white-space:nowrap">top-line</FONT> data from the Phase 3 <FONT STYLE="white-space:nowrap">ABTECT-1</FONT> and <FONT STYLE="white-space:nowrap">ABTECT-2</FONT> induction trials for UC and (ii)&nbsp;the
announcement of its <FONT STYLE="white-space:nowrap">top-line</FONT> data from the Phase 2a induction trial for CD. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company further draws down on the third tranche of the Kreos / Claret Financing, amounting to
&#128;25&nbsp;million and the second tranche of the Heights Financing amounting to &#128;40&nbsp;million, the Company expects to have sufficient funds to finance its operations through the first quarter of 2026. Under these assumptions and based on
its current clinical plan, it would have sufficient funds to finance its operations through the announcement of its <FONT STYLE="white-space:nowrap">top-line</FONT> data from the Phase 3 ABTECT maintenance trial for UC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Underwriting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Global Offering is subject to an
underwriting agreement entered into on October&nbsp;19, 2023. The underwriting agreement does not constitute a &#147;<I>garantie de bonne fin</I>&#148; within the meaning of Article L. <FONT STYLE="white-space:nowrap">225-145</FONT> of the French
Commercial Code (<I>Code de commerce</I>). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Documentation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities referred to in this press release will be offered only by means of a prospectus. When available, copies of the final prospectus relating to and
describing the terms of the proposed Global Offering may be obtained from: Morgan Stanley&nbsp;&amp; Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at prospectus@morganstanley.com; or Leerink
Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) <FONT STYLE="white-space:nowrap">808-7525,</FONT> ext. 6105, or by email at syndicate@leerink.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Application will be made to list the new ordinary shares to be issued pursuant to the Global Offering on Euronext Paris pursuant to a listing prospectus
subject to an approval from the French <I>Autorit&eacute; des march&eacute;s financiers</I> (&#147;<B>AMF</B>&#148;) and comprising (i)&nbsp;the 2023 Universal Registration Document (<I>Document d&#146;Enregistrement Universel 2023</I>) filed with
the AMF on May&nbsp;4, 2023 under number <FONT STYLE="white-space:nowrap">D.23-0394,</FONT> as amended by a first amendment filed with the AMF on September&nbsp;29, 2023 under number
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">D.23-0394-A01,</FONT></FONT> as completed by a second amendment to such 2023 Universal Registration Document, which will be filed with the AMF, and (ii)&nbsp;a Securities Note
(<I>Note d&#146;op&eacute;ration</I>), including a summary of the prospectus. Copies of the 2023 Universal Registration Document are available free of charge at the Company&#146;s head office located at <FONT STYLE="white-space:nowrap">7-11</FONT>
boulevard Haussmann, 75009 Paris, France, on the Company&#146;s website (www.abivax.com) and on the website of the AMF <FONT STYLE="white-space:nowrap">(www.amf-france.org).</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risk Factors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors should carefully consider the
risks factors likely to affect the Company&#146;s business as described in Chapter 3 &#147;Risk Factors&#148; of the 2023 Universal Registration Document, in Chapter 5 of its first amendment and in Chapter 3 of its second amendment and in the risk
factors section of the Company&#146;s registration statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> before marking an investment decision. If any of these risks are realized, the Company&#146;s business, financial condition, operating
results and prospects could be materially and adversely affected. In addition, other risks, not identified or considered significant by the Company, could have the same adverse effect and investors could lose all or part of their investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*** </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Abivax </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abivax is a clinical-stage biotechnology
company focused on developing therapeutics that harness the body&#146;s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Based in France and the U.S., Abivax&#146;s lead drug candidate,
obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts: </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abivax Communications</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regina Jehle</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">regina.jehle@abivax.com</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+33 6 24 60 69 63</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abivax Investor Relations</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patrick Malloy</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">patrick.malloy@abivax.com</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+1 847 987 4878</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*** </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
certain forward-looking statements with respect to the Global Offering, including: the completion of the Global Offering, use of proceeds from the Global Offering, as well as statements regarding Abivax&#146;s clinical development plans, business
and regulatory strategy, and anticipated future performance. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, including
related to progression of, and results from, its ongoing and planned clinical trials, including clinical trials for obefazimod, review and approvals by regulatory authorities, such as the FDA or the EMA, of its drug candidates and the Company&#146;s
continued ability to raise capital to fund its development, including as part of the proposed Global Offering, the Company&#146;s ability to obtain, maintain, protect and enforce its intellectual property rights, as well as those discussed or
identified in the Company&#146;s registration statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> filed with the U.S. Securities and Exchange Commission and the Company&#146;s public filings with the AMF, in particular in the 2023
Universal Registration Document, as amended, for additional information in relation to such factors, risks and uncertainties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than as required by
applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer
to buy or subscribe to shares in the Company in any country. This press release has been prepared in both French and English. In the event of any differences between the two versions of the press release, the French language version shall supersede.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Disclaimers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of ordinary shares or ADSs in any
state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are
required to inform themselves about and to observe any such potential local restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A French listing prospectus comprising (i)&nbsp;the 2023
Universal Registration Document (<I>Document d&#146;Enregistrement Universel 2023</I>) filed with the AMF on May&nbsp;4, 2023 under number <FONT STYLE="white-space:nowrap">D.23-0394,</FONT> as amended by a first amendment filed with the AMF on
September&nbsp;29, 2023 under number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">D.23-0394-A01,</FONT></FONT> as completed by a second amendment to such 2023 Universal Registration Document, which will be filed with the AMF,
and (ii)&nbsp;a Securities Note (<I>Note d&#146;op&eacute;ration</I>), including a summary of the prospectus, will be submitted to the approval by the AMF and will be published on the AMF&#146;s website at
<FONT STYLE="white-space:nowrap">www.amf-france.org.</FONT> Following the filing of the second amendment to the 2023 Universal Registration Document with the AMF, copies of Company&#146;s 2023 Universal Registration Document, as amended, will be
available free of charge at the Company&#146;s head office located at <FONT STYLE="white-space:nowrap">7-11</FONT> boulevard Haussmann, 75009 Paris, France. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European Economic Area </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In relation to each Member
State of the European Economic Area (each, a &#147;<B>Relevant State</B>&#148;), no offer to the public of ordinary shares and ADSs may be made in that Relevant State other than: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined under Article 2(e) of the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus
Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I> that no such offer of the securities shall require the Company or any of its representatives to publish a prospectus pursuant to Article 3 of
the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the
expression an &#147;offer to the public&#148; in relation to the securities in any Relevant State means the communication in any form and by any means presenting sufficient information on the terms of the offer and any securities to be offered so as
to enable an investor to decide to purchase any securities, and the expression &#147;<B>Prospectus Regulation</B>&#148; means Regulation (EU) 2017/1129 of June&nbsp;14, 2017, as amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>France </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities have not been and will not be offered or sold to the public in the Republic of France, and no offering of this prospectus or any marketing
materials relating to securities may be made available or distributed in any way that would constitute, directly or indirectly, an offer to the public in the Republic of France (except for public offerings defined in Article <FONT
STYLE="white-space:nowrap">L.411-2</FONT> 1&deg; of the French Monetary and Financial Code (<I>Code mon&eacute;taire et financier</I>)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities
may only be offered or sold in France pursuant to Article L. <FONT STYLE="white-space:nowrap">411-2</FONT> 1&deg; of the French Monetary and Financial&nbsp;Code (<I>Code </I><I>mon</I><I>&eacute;</I><I>taire</I><I> et financier</I>) to qualified
investors (<I>investisseurs</I><I> </I><I>qualifi</I><I>&eacute;</I><I>s</I>) (as such term is defined in Article 2(e) of the Prospectus Regulation) acting for their own account, and in accordance with Articles L.
<FONT STYLE="white-space:nowrap">411-1,</FONT> L. <FONT STYLE="white-space:nowrap">411-2</FONT> and D. <FONT STYLE="white-space:nowrap">411-2</FONT> to <FONT STYLE="white-space:nowrap">D.411-4</FONT> of the French Monetary and Financial&nbsp;Code
(<I>Code </I><I>mon</I><I>&eacute;</I><I>taire</I><I> et financier</I>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement is not an advertisement and not a prospectus within the
meaning of the Prospectus Regulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g609070g43a95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g43a95.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1.64&AO=&]S:&]P(#,N,  X0DE-! 0
M    $WJ^288X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 )3,S  !  $ E,S,
M  $  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))301$       0     @
M D    )      #A"24T$'@      !      X0DE-!!H      T$    &
M          !F   "E     8 4@!I &0 90!R #$    !
M          $              I0   !F                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   !F     %)G:'1L;VYG   "E     9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG    9@    !29VAT;&]N9P   I0    #=7)L5$585     $
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M!!$       $! #A"24T$%       !     (X0DE-! P     ".H    !
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M" D*"Q   00! P($ @4'!@@% PPS 0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0'_P  1"  A -,# 1$  A$! Q$!_\0 '@   @(" P$!
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MI%;Q6G*D-([92GC97=79XHI<,LHB X98\A_>?>^?TD(TJ]3[Q_<##3LL&\;
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M.-M/K<;0M65I3A6<YZT70O14=9<;X*RCI:L1T-*8UJJ>&H5"U0P8HLR.%)
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M[D&25WE9W9ZJA0%&3CM)R3[Y/[#N &J?TSN/1N_>YQ=MM\NK:N,T1!;&M"V
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MNE?!#44TJR02=V,J1G.\I.=Y<;I4@%7!!P<X<AQ@XQ:NXEZHA=3ZLBO1P _
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MW@SAS]?_ "+^[#7?YJ>JD]>O:KW/V?\ Q6X_ZKIQX+'Y3^E?JZGO!G#GZ_\
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M_P!MZ]\+/D#TG_#4_3$%W_@STG[ZDO\ D=T>L51?\P5W]%Q?K>CPL^0/2?\
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@6]L'VS-\0?SB:-:+@?G2)_$]\H=ZW$_MK^<?,-&O_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
